Latest Morning Briefing Stories
“What we’ve got to do is dramatically reduce the number of pills that are out there, and make sure that the pills that are out there are being used properly,” Judge Dan Polster said. In other opioid news: Native American tribes sue manufacturers over their role in the crisis, doctors start to shift from zero-pain goals for patients, officials in Philadelphia mull safe-injection sites, and more.
The failure may mark the unraveling of an approach to Alzheimer’s treatment that has held hope: increasing the supply of the brain chemical serotonin in patients. Scientists and investors, however, still remain optimistic that eventually a drug will be developed that can fight Alzheimer’s.
At his second Senate hearing, Alex Azar was grilled by Democrats on the Finance Committee questioning his commitment to bringing down high drug costs because of his ties to the pharmaceutical industry. Azar shied away from endorsing the idea of the government to negotiating prices, a concept touted by President Donald Trump.
Alex Azar, however, enjoys strong support from Republicans on the Finance Committee, so it’s unlikely the hearing will damage his path to confirmation.
Naloxone is increasingly seen as the first line of defense in an opioid overdose. When administered within the first minutes — even up to an hour or more — of a potentially deadly overdose, it can resuscitate a victim
A particularly nasty strain of the flu is sweeping the country–flooding emergency rooms, draining medication resources, and racking up a higher-than-normal death toll. But it’s still not too late to get a flu shot.
The J.P. Morgan Healthcare Conference, the biggest annual investors event in biotechnology, is underway and the worries from last year haven’t exactly carried over into 2018. In other pharmaceutical news: an Alzheimer’s drug may have gotten its second wind; Celgene has agreed to buy cancer drugmaker Impact Biomedicines; and an executive facing sexual harassment allegations still hasn’t stepped down.
Tired of playing defense and looking to capitalize on Republicans’ fumbles, Democrats are encouraging people in the party to think big, with ideas ranging from single-payer, government-run care for all, to new insurance options anchored in popular programs like Medicare or Medicaid. In other news from Capitol Hill: medical research legislation, entitlement overhaul, “right-to-try” bills, and CHIP funding.
Alex Azar, the Trump administration’s pick to head the Department of Health and Human Services, is set to testify before the Senate Finance Committee this week, where it’s likely his close ties to the pharmaceutical industry will take center stage with his critics.
Experts credit a decline in tobacco use for the improved rates, along with breakthrough drugs that have improved the chance of surviving a diagnosis. In other public health news: the IV bag shortage linked to the hurricane in Puerto Rico may be over soon; a study finds that antioxidants don’t ease muscles after exercise; and more.
A “surprising” study finds that while many think it’s a problem, only a small number of Americans think the opioid epidemic rises to the level of an emergency.
But the influx of the medications might help the companies’ bottom lines because generics generally have a higher margin than name-brand drugs. Meanwhile, the industry is primed for another wave of mega-mergers in the coming year.
Attorney General Jeff Sessions says he is revoking an Obama-era policy that was deferential to states’ permissive marijuana laws, but it’s not clear exactly what that means. However, the industry, which was riding a high from California legalizing recreational marijuana use, is worried.
Participants in the court, which recognizes failure as part of the process and not something that should be punished, are required to appear daily before Judge Craig D. Hannah. Court systems around the country are watching the Buffalo, N.Y., initiative as a potential model. Media outlets report on news from the drug crisis out of California and Tennessee as well.
Medicare Advantage Disenrollment Period, which is open until Feb. 14, allows people enrolled in an Advantage plan for 2018 to switch to original Medicare. Meanwhile, in other Medicare news, the Centers for Medicare & Medicaid Services will start reviewing Advantage networks on three-year cycles.
The biggest generic threat to Allergan is to its eye treatment drug Restasis. The company has taken various steps to shield Restasis from competition, notably selling its patents to an Indian tribe in New York state to avoid a U.S. Patent and Trademark Office hearing on the validity of the drug’s patents.
In a novel arrangement, drugmaker Spark Therapeutics will offer discounts based on whether or not the drug, Luxturna, works initially and remains effective.
News outlets report on stories related to pharmaceutical pricing.
The van parks outside Baltimore Central Booking and Intake Center with a sign advertising its services to try to help people right as they’re released from jail.
Alex Azar, who has been tapped to replace former Health and Human Services Secretary Tom Price, has been criticized for his close ties to the pharmaceutical industry.